Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial involved 40 people in total — 18 described as healthy controls and 22 with a condition called metabolic syndrome (a cluster of factors such as high blood sugar, excess waist fat, and high blood pressure that can raise the risk of other health conditions). Participants were split into four groups and each person received both the study drug (acipimox, a medication that affects fat metabolism) and a placebo (a dummy treatment with no active ingredient) on separate occasions, in different orders. The trial was measuring two main things: how well blood vessels dilate (widen) in response to increased blood flow — a test called "flow-mediated dilation" — and how well the body uses glucose (sugar) in response to insulin, assessed using a specialised test called a hyperinsulinaemic-euglycaemic clamp. The reported data shows the following flow-mediated dilation figures (expressed as a percentage of how much an artery widened): healthy controls on placebo recorded 10.65%, and on acipimox recorded 11.57%; participants with metabolic syndrome on placebo recorded 8.79%, and on acipimox recorded 9.52%. For the second primary outcome — the measure of how the body handles glucose with insulin — the data was not reported for any group in the results submitted to ClinicalTrials.gov, so no numbers are available for that measurement. A small number of participants did not complete the second study visit: one healthy control, two participants with metabolic syndrome in one group, and two in the other. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Type 2 Diabetes Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with type 2 diabetes (as defined by the National Diabetes Data Group)
- People who have a normal heart and blood vessel check-up result
- People who have not smoked for at least 1 year before joining
- Healthy volunteers with no known medical problems
- Healthy volunteers with a normal heart and blood vessel check-up result
- Healthy volunteers whose fasting blood sugar level is below 110 mg/dL
- Healthy volunteers who have not smoked for at least 1 year before joining
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
For people with type 2 diabetes:
- People with high blood pressure that is not being treated (above 140/90 mmHg)
- People with high cholesterol that is not being treated (LDL above the 75th percentile for their age)
- People who have smoked cigarettes within the past year
- People who have nerve damage that requires medication
- People who have kidney problems, including high levels of protein in the urine or high creatinine levels in the blood
- People with an abnormal heart or blood vessel check-up result
- People who have taken a type of diabetes medication called a thiazolidinedione within the past year
- Women who have gone through menopause and are taking hormone replacement therapy
- People taking ACE inhibitors or angiotensin receptor blockers (a type of blood pressure medication) should be aware that they may need to stop these for 2 weeks before taking the study drug (confirm with trial site)
For healthy volunteers:
- People with an abnormal heart or blood vessel check-up result
- People who are currently taking any prescription medications
- People whose fasting blood sugar level is 110 mg/dL or higher
- People who have smoked cigarettes within the past year
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Flow-mediated Dilation After Placebo or Acipimox Treatment Between Healthy Controls and Those With Metabolic Syndrome; Difference in Insulin-mediated Skeletal Muscle Glucose Utilization Between Test Agent and Placebo
Other options
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.